Metrology for innovative nanotherapeutics

Réseau de sites JRP - LNE
The METRINO project is an ambitious European collaborative initiative funded by the European Partnership on Metrology, aiming to establish Europe as a leader in nanomedicine metrology.
METRINO focus on developing and validating traceable measurement methods and reference materials for the quality assessment of innovative medicinal products and medical devices containing nanomaterials, including synthetic lipid-based particles such as liposomes and LNPs-RNA, and metal oxide nanoparticles tailored for clinical formulations.
MetrINo aims to support industrial stakeholders in implementing regulatory directives (e.g. EMA, MDR, and FDA), as well as contribute to the development of suitable reference materials and consensus standards.
We believe METRINO has the potential to transform the European nanomedicine landscape, ultimately leading to improved patient outcomes and a more competitive European health technology industry.
With the approval of innovative nanotherapeutics, we need to «develop and standardise new testing methods related to the quality and safety assessment of nanomedicines», to reach an understanding of «the critical quality attributes of a given product and the relationship between those and its biological activity and in-vivo behaviour».
METRINO will develop and standardise traceable measurement methods and reference materials that are fit for purpose for assessing the quality of clinical formulations containing LNP-RNA, liposomes and metal oxide nanoparticles.
Starting date: 1st June 2023
Duration: 3 years
Budget: 2.6 MEuro
Coordinated by the French National Metrology Institute (LNE), the multidisciplinary consortium comprises of 9 metrology institutes, the Nanomedicine European Technology Platform, 2 SMEs, 1 pharmaceutical company, 1 hospital, and 6 academic partners.
The project 22HLT04 MetrINo has received funding from the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EURAMET. Neither the European Union nor the granting authority can be held responsible for them.